TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
TEVA PHARMACEUTICAL INDUSTRIES LTD
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$41.31−0.19 (-0.46%)
Close on Oct 19, 2026
- Market cap
- $48.13B
- P/E (TTM)
- 68.9
- Dividend yield
- –
TEVA PHARMACEUTICAL INDUSTRIES LTD revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States [Member] | $8.36B | $8.45B | $9.19B | $7.78B | $7.52B | $7.85B | $8.03B | $8.33B | $8.00B | $7.78B | $7.73B | – | 59.3% | +11.2% |
| Europe [Member] | $5.15B | $5.19B | $5.04B | $5.08B | $5.11B | $5.03B | $5.10B | $5.09B | $4.98B | $4.93B | $4.84B | $4.62B | 36.5% | +0.8% |
| International Markets [Member] | $2.16B | $2.10B | $2.16B | $2.30B | $2.35B | $2.45B | $2.46B | $2.40B | $2.38B | $2.37B | $2.35B | $2.68B | 15.3% | -8.2% |
| Other Activities [Member] | $1.64B | $1.61B | $870.00M | $1.62B | $1.65B | $1.30B | $944.00M | $948.00M | $936.00M | $932.00M | $926.00M | $953.00M | 11.6% | -0.2% |
| North America [Member] | – | – | – | – | – | – | – | – | – | – | $8.12B | $7.76B | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Segment [Member] | $4.26B | $5.00B | $5.00B | $4.56B | $4.46B | $4.37B | $4.31B | $4.71B | $4.50B | $4.44B | $4.34B | $3.89B | -4.6% |
| United States [Member] | $2.55B | $3.32B | $3.36B | $2.72B | $2.53B | $2.46B | $2.30B | $2.70B | $2.52B | $2.41B | $2.39B | – | +0.6% |
| Europe [Member] | $1.38B | $1.38B | $1.30B | $1.43B | $1.50B | $1.48B | $1.58B | $1.60B | $1.56B | $1.56B | $1.48B | $1.38B | -8.4% |
| International Markets [Member] | $329.00M | $304.00M | $336.00M | $407.00M | $421.00M | $420.00M | $440.00M | $408.00M | $416.00M | $475.00M | $465.00M | $509.00M | -21.9% |
| Other Segments [Member] | -$98.00M | -$85.00M | -$90.00M | -$22.00M | $2.00M | $17.00M | $18.00M | $0 | $11.00M | $32.00M | $24.00M | $59.00M | -5000.0% |
| North America [Member] | – | – | – | – | – | – | – | – | – | – | $2.40B | $2.06B | – |
| Segments and Other Activities [Member] | – | – | – | – | – | – | – | $4.71B | $4.51B | $4.47B | $4.36B | $3.95B | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sale of Goods [Member] | $14.57B | $14.60B | $14.61B | $14.36B | $14.17B | $14.18B | $14.05B | $13.89B | $13.47B | $13.16B | $12.98B | $13.04B | 103.3% | +2.8% |
| Distribution [Member] | $1.62B | $1.56B | $1.55B | $1.58B | $1.56B | $1.57B | $1.58B | $1.57B | $1.55B | $1.57B | $1.62B | $1.67B | 11.5% | +3.5% |
| Licensing Arrangements [Member] | $672.00M | $681.00M | $678.00M | $180.00M | $179.00M | $169.00M | $173.00M | $668.00M | $676.00M | $678.00M | $681.00M | $184.00M | 4.8% | +275.4% |
| Other [Member] | $457.00M | $504.00M | $423.00M | $660.00M | $711.00M | $700.00M | $745.00M | $651.00M | $596.00M | $596.00M | $570.00M | $373.00M | 3.2% | -35.7% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $8.36B | $8.45B | $9.19B | $7.78B | $7.52B | $7.85B | $8.03B | $8.33B | $8.00B | $7.78B | $7.73B | – | 59.3% | +11.2% |
| Europe [Member] | $5.15B | $5.19B | $5.04B | $5.08B | $5.11B | $5.03B | $5.10B | $5.09B | $4.98B | $4.93B | $4.84B | $4.62B | 36.5% | +0.8% |
| North America [Member] | – | – | – | – | – | – | – | – | – | – | $8.12B | $7.76B | – | – |
From the segment and revenue-disaggregation notes of Teva Pharmaceutical Industries's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.